Positions

Overview

  • I am Associate Dean for Global Health in the School of Medicine, Director of the UAB Center for AIDS Research and a Professor of Medicine in the Division of Infectious Diseases. I am also the principal investigator of the CFAR Network of Integrated Clinical Systems (CNICS), an NIAID-funded National Network of EMR-collected clinical data at 8 CFAR centers that are merged for the purposes of clinical research. I am the founding director of the UAB 1917 HIV Clinic, which has pioneered treatment programs based on real world clinical trials and studies focused on quality improvement in the area of HIV. I serve as Co-PI of the NA-ACCORD, an international collaboration of more than 30 sites that merge data for comparative effectiveness research, and also serve on the Executive Steering Committee of the ART-CC, an international cohort research group. I have served on the Board of Directors of the American Board of Internal Medicine (and as Chair of the Infectious Disease Subspecialty Board) and the NIH Office of AIDS Research Advisory Council. I am past President of the HIV Medical Association, a member and current Chair of the IAS-USA Guidelines Panel on Antiretroviral Therapy, a Co-Chair of the AASLD/IDSA/IAS-USA HCV Treatment Guidelines group, and serve on numerous state, local, and national committees. I am Co-Editor of the Sanford Guide for Antimicrobial Therapy and the Sanford HIV Guide and the Sanford Hepatitis Guide. I have had over 25 trainees who have gone on to successful academic careers and I have published over 450 manuscripts during the course of my career. In 1996, I was listed as one of the top ten cited HIV researchers by Science (1996) and received seven Argus Awards for Best Lectures to the 1st year medical student at UAB (2009-10,2013,2015-17). In 2014 I was selected as the Castle-Connelly Physician of the year and was inducted into the Alabama Healthcare Hall of Fame. In 2014, I published a memoir “Positive: One Doctors encounters with Death, Life, and the US Healthcare System.” (http://www.positivethebook.com)
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Measurement of the nuclear modification factor for inclusive jets in Pb+Pb collisions at sNN=5.02 TeV with the ATLAS detectorPhysics Letters B.  790:108-128. 2019
    2019 Observation of Two Resonances in the Λb0 π± Systems and Precise Measurement of Σb± and Σb∗± PropertiesPhysical Review Letters.  122. 2019
    2019 Measurement of the Charm-Mixing Parameter yCPPhysical Review Letters.  122. 2019
    2019 Search for heavy Majorana or Dirac neutrinos and right-handed W gauge bosons in final states with two charged leptons and two jets at √s=13 TeV with the ATLAS detectorJournal of High Energy Physics.  2019. 2019
    2018 Associations of food insecurity and psychosocial measures with diet quality in adults aging with HIV.AIDS Care.  1-9. 2018
    2018 Evidence for an ηc(1 S) π- resonance in B0→ ηc(1 S) K+π- decaysEuropean Physical Journal C: Particles and Fields.  78. 2018
    2018 Measurement of the Zγ→ νν¯ γ production cross section in pp collisions at √s=13 TeV with the ATLAS detector and limits on anomalous triple gauge-boson couplingsJournal of High Energy Physics.  2018. 2018
    2018 Measurement of the azimuthal anisotropy of charged particles produced in √sNN = 5.02 TeV Pb+Pb collisions with the ATLAS detectorEuropean Physical Journal C: Particles and Fields.  78. 2018
    2018 Operation and performance of the ATLAS Tile Calorimeter in Run 1European Physical Journal C: Particles and Fields.  78. 2018
    2018 Search for Higgs boson pair production in the γγWW channel using pp collision data recorded at √s = 13 TeV with the ATLAS detectorEuropean Physical Journal C: Particles and Fields.  78. 2018
    2018 Search for lepton-flavour-violating decays of Higgs-like bosonsEuropean Physical Journal C: Particles and Fields.  78. 2018
    2018 Search for new phenomena in events with same-charge leptons and b-jets in pp collisions at √s=13 TeV with the ATLAS detectorJournal of High Energy Physics.  2018. 2018
    2018 Search for pair and single production of vectorlike quarks in final states with at least one Z boson decaying into a pair of electrons or muons in pp collision data collected with the ATLAS detector at s =13 TeVPhysical Review D.  98. 2018
    2018 Measurement of Antiproton Production in p-He Collisions at sqrt[s_{NN}]=110  GeV.Physical Review Letters.  121:222001. 2018
    2018 Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply.Journal of the American Medical Association.  320:2154. 2018
    2018 Alcohol Use Patterns and Subsequent Sexual Behaviors Among Women, Men who have Sex with Men and Men who have Sex with Women Engaged in Routine HIV Care in the United States.AIDS and Behavior2018
    2018 Brief Report: Reduced Use of Illicit Substances, Even Without Abstinence, Is Associated With Improved Depressive Symptoms Among People Living With HIV.Journal of Acquired Immune Deficiency Syndromes.  79:283-287. 2018
    2018 Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.AIDS Research and Human Retroviruses.  34:916-921. 2018
    2018 Measurement of dijet azimuthal decorrelations in pp collisions at s =8 TeV with the ATLAS detector and determination of the strong couplingPhysical Review D.  98. 2018
    2018 Search for chargino-neutralino production using recursive jigsaw reconstruction in final states with two or three charged leptons in proton-proton collisions at s =13 TeV with the ATLAS detectorPhysical Review D.  98. 2018
    2018 Search for lepton-flavor violation in different-flavor, high-mass final states in pp collisions at s =13 TeV with the ATLAS detectorPhysical Review D.  98. 2018
    2018 Search for lepton-flavor-violating decays of the Z boson into a τ lepton and a light lepton with the ATLAS detectorPhysical Review D.  98. 2018
    2018 Search for pair production of Higgsinos in final states with at least three b -tagged jets in s =13 TeV pp collisions using the ATLAS detectorPhysical Review D.  98. 2018
    2018 Search for pair production of heavy vectorlike quarks decaying into hadronic final states in pp collisions at s =13 TeV with the ATLAS detectorPhysical Review D.  98. 2018
    2018 Study of ϒ production in pPb collisions at √sNN=8.16 TeVJournal of High Energy Physics.  2018. 2018
    2018 Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort.AIDS and Behavior2018
    2018 Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction.Epidemiology.  30:69-74. 2018
    2018 Chronic hepatitis B virus monoinfection at a university hospital in Zambia.World Journal of Hepatology.  10:622-628. 2018
    2018 HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.Annals of Internal Medicine.  169:376-384. 2018
    2018 Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, multi-centre, prospective audit.Colorectal Disease.  20 Suppl 6:15-32. 2018
    2018 Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes.Journal of Acquired Immune Deficiency Syndromes.  79:77-82. 2018
    2018 A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use.Clinical Infectious Diseases2018
    2018 A Randomized Pilot Trial of a Novel Behavioral Intervention for Chronic Pain Tailored to Individuals with HIV.AIDS and Behavior.  22:2733-2742. 2018
    2018 Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.Journal of the American Medical Association.  320:379-396. 2018
    2018 Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia.AIDS and Behavior.  22:2334-2339. 2018
    2018 Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio.AIDS.  32:1361-1367. 2018
    2018 Assessing effects of behavioral intervention on treatment outcomes among patients initiating HIV care: Rationale and design of iENGAGE intervention trial.Controlled Clinical Trials.  69:48-54. 2018
    2018 Intervention Mapping to develop a Social Cognitive Theory-based intervention for chronic pain tailored to individuals with HIV.Contemporary Clinical Trials Communications.  10:9-16. 2018
    2018 Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study.AIDS2018
    2018 Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States.Clinical Infectious Diseases.  66:1230-1238. 2018
    2018 Predictors of Longitudinal Trajectories of Alcohol Consumption in People with HIV.Alcoholism: Clinical and Experimental Research.  42:561-570. 2018
    2018 The global burden of tuberculosis: results from the Global Burden of Disease Study 2015Lancet Infectious Diseases.  18:261-284. 2018
    2018 Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection.HIV Medicine.  19:132-142. 2018
    2018 Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure.AIDS.  32:347-355. 2018
    2018 Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.Journal of the International AIDS Society.  21. 2018
    2018 Racial disparities in the prevalence and control of hypertension among a cohort of HIV-infected patients in the southeastern United States.PLoS ONE.  13:e0194940. 2018
    2017 Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula.Annals of Epidemiology.  27:783-789.e2. 2017
    2017 Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.Gates Open Research.  1:9. 2017
    2017 Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.Lancet HIV.  4:e486-e494. 2017
    2017 CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).Clinical Infectious Diseases.  65:959-966. 2017
    2017 Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.Journal of Infectious Diseases.  216:S581-S587. 2017
    2017 In Memorium: William Ernest Dismukes 1939-2017.Journal of Infectious Diseases2017
    2017 Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America.Clinical Infectious Diseases.  65:636-643. 2017
    2017 Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.Lancet HIV.  4:e349-e356. 2017
    2017 Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment.AIDS and Behavior.  21:1914-1925. 2017
    2017 The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals.AIDS and Behavior.  21:1878-1884. 2017
    2017 Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee.Retrovirology.  14:35. 2017
    2017 Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.Clinical Infectious Diseases.  64:1591-1596. 2017
    2017 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population.Journal of Acquired Immune Deficiency Syndromes.  75:568-576. 2017
    2017 Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.Clinical Infectious Diseases.  64:1343-1349. 2017
    2017 Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.Lancet HIV.  4:e251-e259. 2017
    2017 Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice.Medicine.  96:e6275. 2017
    2017 Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.Clinical Journal of the American Society of Nephrology.  12:467-475. 2017
    2017 Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States.JAMA Cardiology.  2:260-267. 2017
    2017 Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV.AIDS Research and Human Retroviruses2017
    2017 TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.Journal of Infectious Diseases.  215:599-605. 2017
    2017 Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems.JAMA Cardiology.  2:155-162. 2017
    2017 Erratum: Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1725–1774)(S0140673616315756)(10.1016/S0140-6736(16)31575-6))Lancet.  389:e1. 2017
    2017 Brief Report: Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012.Journal of Acquired Immune Deficiency Syndromes.  74:60-64. 2017
    2016 Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet.  388:1725-1774. 2016
    2016 A Randomized Controlled Trial Protocol to Evaluate the Effectiveness of an Integrated Care Management Approach to Improve Adherence Among HIV-Infected Patients in Routine Clinical Care: Rationale and Design.JMIR Research Protocols.  5:e156. 2016
    2016 Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department.Open Forum Infectious Diseases.  3:ofw211. 2016
    2016 Infection-related and -unrelated malignancies, HIV and the aging population.HIV Medicine.  17:590-600. 2016
    2016 Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.Clinical Infectious Diseases.  63:528-531. 2016
    2016 Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders.AIDS Care.  29:177-184. 2016
    2016 Using Patient Perspectives to Inform the Development of a Behavioral Intervention for Chronic Pain in Patients with HIV: A Qualitative Study.Pain Medicine.  18:879-888. 2016
    2016 Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.Journal of the American Medical Association.  316:191-210. 2016
    2016 When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.Journal of Acquired Immune Deficiency Syndromes.  72:214-221. 2016
    2016 Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.AIDS.  30:1229-1238. 2016
    2016 Suitability of the PROMIS alcohol use short form for screening in a HIV clinical care setting.Drug and Alcohol Dependence.  164:113-119. 2016
    2016 Cost considerations in the current antiretroviral era.AIDS.  30:2115-2119. 2016
    2016 HIV primary care providers--Screening, knowledge, attitudes and behaviors related to alcohol interventions.Drug and Alcohol Dependence.  161:59-66. 2016
    2016 Implementation of Computer-delivered Brief Alcohol Intervention in HIV Clinical Settings: Who Agrees to Participate?Journal of Addiction Research and Therapy.  7. 2016
    2016 Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research.Open Forum Infectious Diseases.  3:ofw109. 2016
    2016 A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.AIDS.  30:869-878. 2016
    2016 Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV.AIDS and Behavior.  20:687-698. 2016
    2016 Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.PLoS ONE.  11:e0160460. 2016
    2016 Cigarette Smokers are Less Likely to Have Undetectable Viral Loads: Results From Four HIV Clinics.Journal of Addiction Medicine.  10:13-19. 2016
    2016 The Silent Epidemic - Frailty and Aging with HIV.Total Patient Care HIV HCV.  1:6-17. 2016
    2015 Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.International Journal of Epidemiology.  45:2038-2049. 2015
    2015 Immunization costs and programmatic barriers at an urban HIV clinic.Clinical Infectious Diseases.  61:1726-1731. 2015
    2015 Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.Annals of the Rheumatic Diseases.  74:2107-2116. 2015
    2015 Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.Hepatology.  62:932-954. 2015
    2015 Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults.AIDS Research and Human Retroviruses.  31:898-904. 2015
    2015 Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.New England Journal of Medicine.  373:705-713. 2015
    2015 Factors Associated with Missed Psychiatry Visits in an Urban HIV ClinicAIDS and Behavior.  19:1423-1429. 2015
    2015 Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.Lancet HIV.  2:e319-e327. 2015
    2015 Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.Journal of Acquired Immune Deficiency Syndromes.  69:439-445. 2015
    2015 Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL.Clinical Infectious Diseases.  61:169-170. 2015
    2015 An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial.Journal of Acquired Immune Deficiency Syndromes.  69:291-298. 2015
    2015 Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.Journal of Acquired Immune Deficiency Syndromes.  69:348-354. 2015
    2015 Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.Journal of Virology.  89:6656-6672. 2015
    2015 Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trialsLancet.  385:2606-2615. 2015
    2015 Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.Lancet.  385:2606-2615. 2015
    2015 Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals.AIDS Research and Human Retroviruses.  31:623-627. 2015
    2015 Short Communication: Viral Suppression Is Associated with Increased Likelihood of Colorectal Cancer Screening Among Persons Living with HIV/AIDS.AIDS Research and Human Retroviruses.  31:519-524. 2015
    2015 Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.Journal of Acquired Immune Deficiency Syndromes.  68:554-561. 2015
    2015 End-stage renal disease among HIV-infected adults in North America.Clinical Infectious Diseases.  60:941-949. 2015
    2015 Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.Hepatology.  61:776-782. 2015
    2015 Preventing HIV in women - Still trying to find their voiceNew England Journal of Medicine.  372:564-566. 2015
    2015 Preventing HIV in women--still trying to find their VOICE.New England Journal of Medicine.  372:564-566. 2015
    2015 Effects on mortality of a nutritional intervention for malnourished HIV-infected adults referred for antiretroviral therapy: a randomised controlled trial.BMC Medicine.  13:17. 2015
    2015 Editorial commentary: Fixing a hole in the HIV safety net.Clinical Infectious Diseases.  60:126-127. 2015
    2015 Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels.AIDS Research and Treatment.  2015:478750. 2015
    2014 HIV/AIDS.Infectious Disease Clinics of North America.  28:ix-x. 2014
    2014 Aberrant drug-related behaviors: a qualitative analysis of medical record documentation in patients referred to an HIV/chronic pain clinic.Pain Medicine.  15:1724-1733. 2014
    2014 Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence.Infectious Disease Clinics of North America.  28:355-369. 2014
    2014 Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics.Clinical Infectious Diseases.  59:725-734. 2014
    2014 HIV/AIDS.Infectious Disease Clinics of North America.  28:xv-xvi. 2014
    2014 Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.PLoS Medicine.  11:e1001718. 2014
    2014 The authors reply.American Journal of Epidemiology.  180:450. 2014
    2014 Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.Journal of the American Medical Association.  312:410-425. 2014
    2014 Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.Clinical Infectious Diseases.  59:287-297. 2014
    2014 Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.Lancet.  383:2222-2231. 2014
    2014 Decline in locomotor functions over time in HIV-infected patients.AIDS.  28:1531-1532. 2014
    2014 Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).International Journal of Epidemiology.  43:691-702. 2014
    2014 HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.Clinical Infectious Diseases.  58:1599-1606. 2014
    2014 Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.Journal of Acquired Immune Deficiency Syndromes.  66:96-101. 2014
    2014 Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.AIDS.  28:979-987. 2014
    2014 Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.American Journal of Epidemiology.  179:996-1005. 2014
    2014 Disparities in the quality of HIV care when using US Department of Health and Human Services indicators.Clinical Infectious Diseases.  58:1185-1189. 2014
    2014 Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients.AIDS patient care.  28:176-182. 2014
    2014 Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.AIDS.  28:717-725. 2014
    2014 A conceptual framework for understanding chronic pain in patients with HIV.Pain Practice.  14:207-216. 2014
    2014 Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic.Pain Medicine.  15:418-424. 2014
    2014 'Two pains together': patient perspectives on psychological aspects of chronic pain while living with HIV.PLoS ONE.  9:e111765. 2014
    2013 Pain is independently associated with impaired physical function in HIV-infected patients.Pain Medicine.  14:1985-1993. 2013
    2013 Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.Journal of Acquired Immune Deficiency Syndromes.  64:254-260. 2013
    2013 The antiretroviral drug pipeline: prospects and implications for future treatment research.Current Opinion in HIV and AIDS.  8:572-578. 2013
    2013 Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapyBMJ Open.  3:927-935. 2013
    2013 Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.Journal of Infectious Diseases.  208:1240-1249. 2013
    2013 A pilot study of screening, brief intervention, and referral for treatment (SBIRT) in non-treatment seeking smokers with HIV.Addictive Behaviors.  38:2541-2546. 2013
    2013 Physical activity and health outcomes among HIV-infected men who have sex with men: a longitudinal mediational analysis.Annals of Behavioral Medicine.  46:149-156. 2013
    2013 Routine depression screening in an HIV clinic cohort identifies patients with complex psychiatric co-morbidities who show significant response to treatment.AIDS and Behavior.  17:2781-2791. 2013
    2013 Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.Clinical Infectious Diseases.  57:756-764. 2013
    2013 Characteristics of an ambulatory palliative care clinic for HIV-infected patients.Journal of Palliative Medicine.  16:934-937. 2013
    2013 When to start antiretroviral therapy: as soon as possible.BMC Medicine.  11:147. 2013
    2013 Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States.AIDS Research and Human Retroviruses.  29:887-891. 2013
    2013 Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.Journal of Acquired Immune Deficiency Syndromes.  63:77-85. 2013
    2013 Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.AIDS Research and Human Retroviruses.  29:698-703. 2013
    2013 Impact of a computer-assisted, provider-delivered intervention on sexual risk behaviors in HIV-positive men who have sex with men (MSM) in a primary care setting.AIDS Education and Prevention.  25:87-101. 2013
    2013 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.Journal of Acquired Immune Deficiency Syndromes.  62:405-413. 2013
    2013 The role of palliative care in the current HIV treatment era in developed countries.Topics in antiviral medicine.  21:20-26. 2013
    2013 Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV.AIDS and Behavior.  17:307-318. 2013
    2013 Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.AIDS Research and Human Retroviruses.  29:105-111. 2013
    2012 Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering.Journal of Acquired Immune Deficiency Syndromes.  61:600-605. 2012
    2012 Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.International Journal of Epidemiology.  41:1807-1820. 2012
    2012 New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings.Topics in antiviral medicine.  20:162-167. 2012
    2012 Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.Clinical Infectious Diseases.  55:1550-1557. 2012
    2012 Editorial commentary. Viva no difference!Clinical Infectious Diseases.  55:1252-1254. 2012
    2012 Linezolid for treatment of chronic extensively drug-resistant tuberculosis.New England Journal of Medicine.  367:1508-1518. 2012
    2012 Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure.Journal of Acquired Immune Deficiency Syndromes.  61:164-170. 2012
    2012 Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.Journal of Antimicrobial Chemotherapy.  67:2020-2028. 2012
    2012 Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.HIV Clinical Trials.  13:228-232. 2012
    2012 Biomarkers to monitor safety in people on art and risk of mortality.Journal of Acquired Immune Deficiency Syndromes.  60:51-58. 2012
    2012 Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.Journal of Acquired Immune Deficiency Syndromes.  60:33-42. 2012
    2012 Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.International Journal of Epidemiology.  41:448-459. 2012
    2012 The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.HIV Medicine.  13:89-97. 2012
    2012 A search for a doubly-charged Higgs boson in pp collisions at √s=7 TeVEuropean Physical Journal C: Particles and Fields.  72:1-26. 2012
    2012 Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention.Journal of Acquired Immune Deficiency Syndromes.  59:86-93. 2012
    2012 Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing.PLoS Pathogens.  8:e1002880. 2012
    2012 HIV infection and obesity: where did all the wasting go?Antiviral Therapy.  17:1281-1289. 2012
    2012 Patient reported outcomes in routine care: advancing data capture for HIV cohort research.Clinical Infectious Diseases.  54:141-147. 2012
    2012 Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.PLoS Medicine.  9:e1001207. 2012
    2011 Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men.Pharmacogenetics -London-.  21:798-807. 2011
    2011 HIV now firmly established in the Middle Ages.Clinical Infectious Diseases.  53:1140-1142. 2011
    2011 Health-related quality of life in the gender, race, and clinical experience trialAIDS Research and Treatment.  2011. 2011
    2011 Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.Journal of Acquired Immune Deficiency Syndromes.  58:253-260. 2011
    2011 Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.Clinical Infectious Diseases.  53:927-935. 2011
    2011 Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.Clinical Infectious Diseases.  53:807-816. 2011
    2011 Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.PLoS Pathogens.  7:e1002209. 2011
    2011 The role of toxicity-related regimen changes in the development of antiretroviral resistance.AIDS Research and Human Retroviruses.  27:957-963. 2011
    2011 Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.Lancet.  378:238-246. 2011
    2011 Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality.Journal of General Internal Medicine.  26:745-750. 2011
    2011 Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.Health Services Research.  46:982-995. 2011
    2011 Age at cancer diagnosis among persons with AIDS.Annals of Internal Medicine.  154:642-643. 2011
    2011 Age at cancer diagnosis among persons with AIDS.Annals of Internal Medicine.  154:642-643. 2011
    2011 Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy.AIDS.  25:691-700. 2011
    2011 Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.Clinical Infectious Diseases.  52:387-395. 2011
    2011 Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3)Clinical Pharmacology and Therapeutics.  89:320. 2011
    2011 Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system.Clinical Infectious Diseases.  52 Suppl 2:S238-S246. 2011
    2011 Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.AIDS.  25:185-195. 2011
    2011 Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life.Journal of the Association of Nurses in AIDS Care.  22:17-25. 2011
    2011 The ghosts of Christmas past. How would those we've lost guide us today?Positively aware : the monthly journal of the Test Positive Aware Network.  23:10-12. 2011
    2011 Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.PLoS ONE.  6:e21189. 2011
    2010 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?AIDS Research and Therapy.  7:45. 2010
    2010 Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.AIDS Research and Human Retroviruses.  26:1279-1285. 2010
    2010 Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.American Journal of Kidney Diseases.  56:872-882. 2010
    2010 Virologic and immunologic response to HAART, by age and regimen class.AIDS.  24:2469-2479. 2010
    2010 Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus.Infection Control and Hospital Epidemiology.  31:1092-1093. 2010
    2010 Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Antimicrobial Agents and Chemotherapy.  54:4137-4142. 2010
    2010 Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.Clinical Infectious Diseases.  51:718-724. 2010
    2010 Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.Journal of Virology.  84:8712-8720. 2010
    2010 Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.Journal of Acquired Immune Deficiency Syndromes.  54:442-444. 2010
    2010 Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients.HIV Medicine.  11:462-468. 2010
    2010 Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.AIDS.  24:1717-1726. 2010
    2010 How do HIV elite controllers do what they do?Clinical Infectious Diseases.  51:239-241. 2010
    2010 Erratum: Treatment with Recombinant Growth Hormone Is Associated with Modest Improvement in CD4 Lymphocyte Reconstitution in HIV-Infected Persons on Antiretroviral Therapy: Results of ACTG A5174 (AIDS Research and Human Retroviruses (2010) 26 (425-432))AIDS Research and Human Retroviruses.  26:839. 2010
    2010 Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9).AIDS Care.  22:874-885. 2010
    2010 Late presentation for human immunodeficiency virus care in the United States and Canada.Clinical Infectious Diseases.  50:1512-1520. 2010
    2010 Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Journal of Infectious Diseases.  201:1481-1487. 2010
    2010 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.Clinical Infectious Diseases.  50:1387-1396. 2010
    2010 Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.HIV Clinical Trials.  11:125-132. 2010
    2010 Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting.Clinical Infectious Diseases.  50:1165-1173. 2010
    2010 Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.AIDS Research and Human Retroviruses.  26:425-432. 2010
    2010 Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.Journal of Infectious Diseases.  201:803-813. 2010
    2010 A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics.PLoS ONE.  5:e9680. 2010
    2010 Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care.Clinical Infectious Diseases.  50:574-584. 2010
    2010 Antiretroviral prescribing patterns in treatment-naïve patients in the United States.AIDS patient care.  24:79-85. 2010
    2010 Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing.Journal of Acquired Immune Deficiency Syndromes.  53:215-221. 2010
    2010 Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.American Journal of Epidemiology.  171:198-205. 2010
    2009 HIV/AIDS: the only thing constant...Journal of the National Medical Association.  101:1299-1300. 2009
    2009 Modeling sequence evolution in acute HIV-1 infection.Journal of Theoretical Biology.  261:341-360. 2009
    2009 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.Clinical Infectious Diseases.  49:1582-1590. 2009
    2009 Gender differences in discontinuation of antiretroviral treatment regimens.Journal of Acquired Immune Deficiency Syndromes.  52:336-341. 2009
    2009 Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].Current Opinion in HIV and AIDS.  4:513-517. 2009
    2009 Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.AIDS.  23:2199-2208. 2009
    2009 Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.AIDS.  23:1539-1546. 2009
    2009 Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.Journal of Experimental Medicine.  206:1273-1289. 2009
    2009 A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.Journal of Infectious Diseases.  199:1638-1647. 2009
    2009 Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.International Journal of Epidemiology.  38:746-756. 2009
    2009 HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.Clinical Infectious Diseases.  48:1335-1344. 2009
    2009 Ryan White: an unintentional home builder.Aids Reader -New York-.  19:166-168. 2009
    2009 Ryan White: an unintentional home builder.Aids Reader -New York-.  19:166-168. 2009
    2009 Effect of early versus deferred antiretroviral therapy for HIV on survival.New England Journal of Medicine.  360:1815-1826. 2009
    2009 Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.Clinical Infectious Diseases.  48:1138-1151. 2009
    2009 Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.Clinical Infectious Diseases.  48:787-794. 2009
    2009 Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.Journal of Clinical Epidemiology.  62:321-327.e7. 2009
    2009 Missed visits and mortality among patients establishing initial outpatient HIV treatment.Clinical Infectious Diseases.  48:248-256. 2009
    2009 Racial disparities in HIV virologic failure: do missed visits matter?Journal of Acquired Immune Deficiency Syndromes.  50:100-108. 2009
    2009 The therapeutic implications of timely linkage and early retention in HIV care.AIDS patient care.  23:41-49. 2009
    2008 Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.Journal of Infectious Diseases.  198:1345-1352. 2008
    2008 Short-term discontinuation of HAART regimens more common in vulnerable patient populations.AIDS Research and Human Retroviruses.  24:1347-1355. 2008
    2008 Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.New England Journal of Medicine.  359:1442-1455. 2008
    2008 Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.International Journal of Epidemiology.  37:948-955. 2008
    2008 Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.AIDS.  22:1951-1960. 2008
    2008 Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.AIDS.  22:1821-1827. 2008
    2008 Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.AIDS Research and Human Retroviruses.  24:1031-1035. 2008
    2008 An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).AIDS Research and Human Retroviruses.  24:805-813. 2008
    2008 Gastrointestinal complications of HIV infection: changing priorities in the HAART era.Gut.  57:861-870. 2008
    2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.Proceedings of the National Academy of Sciences.  105:7552-7557. 2008
    2008 Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.AIDS.  22:957-962. 2008
    2008 Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic.Clinical Infectious Diseases.  46:1315-1318. 2008
    2008 Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.Journal of Acquired Immune Deficiency Syndromes.  47:553-558. 2008
    2008 AIDS therapy, third editionAids Reader -New York-.  18. 2008
    2008 High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.Clinical Infectious Diseases.  46:1111-1118. 2008
    2008 Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.Journal of Interferon and Cytokine Research.  28:89-100. 2008
    2008 Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.Antiviral Therapy.  13:959-967. 2008
    2007 Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.Journal of Acquired Immune Deficiency Syndromes.  46:607-615. 2007
    2007 Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection?Clinical Infectious Diseases.  45 Suppl 4:S261-S265. 2007
    2007 Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.Clinical Infectious Diseases.  45:658-661. 2007
    2007 Failure to establish HIV care: characterizing the "no show" phenomenon.Clinical Infectious Diseases.  45:127-130. 2007
    2007 CMS physics technical design report, volume II: Physics performanceJournal of Physics G: Nuclear and Particle Physics.  34:995-1579. 2007
    2007 Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings.Journal of Acquired Immune Deficiency Syndromes.  44:525-530. 2007
    2007 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).International Journal of Epidemiology.  36:294-301. 2007
    2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.Arthritis and Rheumatism.  56:1125-1133. 2007
    2007 Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.AIDS.  21:F11-F18. 2007
    2007 HIV care at a crossroads: the emerging crisis in the US HIV epidemic.MedGenMed : Medscape general medicine.  9:58. 2007
    2007 Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?Clinical Infectious Diseases.  44:135-138. 2007
    2007 HIV discrimination and the health of women living with HIV.Women and Health.  46:99-112. 2007
    2006 Which policy to ADAP-T: waiting lists or waiting lines?Clinical Infectious Diseases.  43:1365-1367. 2006
    2006 A plea for justice for jailed medical workers.Science.  314:924-925. 2006
    2006 Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum.Journal of Acquired Immune Deficiency Syndromes.  43:378-380. 2006
    2006 Ryan White CARE Act reauthorization: we need help.Aids Reader -New York-.  16:594-596. 2006
    2006 Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.Journal of Infectious Diseases.  194:623-632. 2006
    2006 Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.Journal of the American Medical Association.  296:782-793. 2006
    2006 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.Journal of the American Medical Association.  296:827-843. 2006
    2006 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.Topics in HIV Medicine.  14:827-843. 2006
    2006 Ryan White CARE Act reauthorization: we need help.Topics in HIV Medicine.  14:93-94. 2006
    2006 The experts speak. Burn-out among HIV care providers. Interview by Vicki Glaser.AIDS patient care.  20:385-390. 2006
    2006 Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.MedGenMed : Medscape general medicine.  8:36. 2006
    2006 Distribution of health care expenditures for HIV-infected patients.Clinical Infectious Diseases.  42:1003-1010. 2006
    2006 Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.Clinical Infectious Diseases.  42:870-877. 2006
    2006 Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.AIDS Research and Human Retroviruses.  22:232-239. 2006
    2006 Roundtable. Who should be providing HIV care?Aids Clinical Care.  18:21-24. 2006
    2006 Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.AIDS Research and Human Retroviruses.  22:125-131. 2006
    2006 Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.Clinical Infectious Diseases.  42:126-131. 2006
    2006 Sustained HIV viral suppression following treatment interruption: an observational study.AIDS Research and Human Retroviruses.  22:40-44. 2006
    2005 Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.Nature Medicine.  11:1170-1172. 2005
    2005 Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature.AIDS Research and Human Retroviruses.  21:753-756. 2005
    2005 Antigenic conservation and immunogenicity of the HIV coreceptor binding site.Journal of Experimental Medicine.  201:1407-1419. 2005
    2005 Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care.Sexually Transmitted Diseases.  32:20-26. 2005
    2004 Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.Journal of Experimental Medicine.  200:1243-1256. 2004
    2004 Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.Clinical Infectious Diseases.  39:1380-1384. 2004
    2004 A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program.Journal of Acquired Immune Deficiency Syndromes.  37 Suppl 2:S58-S67. 2004
    2004 Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.AIDS Research and Human Retroviruses.  20:1037-1045. 2004
    2004 Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.Journal of the American Medical Association.  292:180-189. 2004
    2004 Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.Journal of the American Medical Association.  292:251-265. 2004
    2004 Initiation of antiretroviral therapy: implications of recent findings.Topics in HIV Medicine.  12:83-88. 2004
    2004 Anemia in HIV infection: clinical impact and evidence-based management strategies.Clinical Infectious Diseases.  38:1454-1463. 2004
    2004 Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.Journal of Acquired Immune Deficiency Syndromes.  35:239-252. 2004
    2003 HIV protease inhibitor ritonavir induces lipoatrophy in male mice.AIDS Research and Human Retroviruses.  19:1141-1150. 2003
    2003 A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.HIV Clinical Trials.  4:287-300. 2003
    2003 A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.Journal of Infectious Diseases.  188:625-634. 2003
    2003 Antiretroviral therapy: select lessons from recent studies.Topics in HIV Medicine.  11:164-168. 2003
    2003 Duration of highly active antiretroviral therapy regimens.Clinical Infectious Diseases.  37:714-722. 2003
    2003 Is it time to proactively switch successful antiretroviral therapy? Carefully check your SWATCH.Annals of Internal Medicine.  139:148-149. 2003
    2003 Erratum: Antibody neutralization and escape by HIV-1 (Nature (2003) 422 (307-312))Nature.  423:197. 2003
    2003 Antibody neutralization and escape by HIV-1.Nature.  422:307-312. 2003
    2002 Enfuvirtide.Expert Opinion on Investigational Drugs.  11:1837-1843. 2002
    2002 Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.Journal of Acquired Immune Deficiency Syndromes.  31:257-275. 2002
    2002 Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.International Journal of Epidemiology.  31:951-958. 2002
    2002 Patient-perceived barriers to antiretroviral adherence: associations with race.AIDS Care.  14:607-617. 2002
    2002 Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.Journal of Infectious Diseases.  186:626-633. 2002
    2002 Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.AIDS Research and Human Retroviruses.  18:909-916. 2002
    2002 Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.Journal of the American Medical Association.  288:222-235. 2002
    2002 The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.AIDS Research and Human Retroviruses.  18:685-693. 2002
    2002 Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Antimicrobial Agents and Chemotherapy.  46:1896-1905. 2002
    2002 A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.AIDS.  16:579-588. 2002
    2001 Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.Clinical Infectious Diseases.  33:1914-1921. 2001
    2001 Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).AIDS.  15:1971-1978. 2001
    2001 Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.AIDS Research and Human Retroviruses.  17:1379-1385. 2001
    2001 Toward a definition of HIV expertise: a survey of experienced HIV physicians.AIDS patient care.  15:321-330. 2001
    2001 HIV resistance testing in clinical practice: a Qaly-fied success.Annals of Internal Medicine.  134:475-477. 2001
    2001 Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.Journal of Infectious Diseases.  183:563-570. 2001
    2001 Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.Journal of Infectious Diseases.  183:401-408. 2001
    2000 The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3American Journal of Gastroenterology.  95:3142-3146. 2000
    2000 The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3.American Journal of Gastroenterology.  95:3142-3146. 2000
    2000 Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.Clinical Infectious Diseases.  31:1095-1097. 2000
    2000 Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.Antimicrobial Agents and Chemotherapy.  44:2672-2678. 2000
    2000 Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.Annals of Internal Medicine.  133:435-438. 2000
    2000 Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.AIDS Research and Human Retroviruses.  16:1123-1133. 2000
    2000 Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.Clinical Infectious Diseases.  30:749-756. 2000
    2000 Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.Clinical Infectious Diseases.  30:710-718. 2000
    2000 Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.Journal of the American Medical Association.  283:381-390. 2000
    2000 Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.Clinical Infectious Diseases.  30:47-54. 2000
    2000 Health-related quality of life and virologic outcomes in an HIV clinic.Quality of Life Research.  9:977-985. 2000
    1999 Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.Journal of Infectious Diseases.  180:1851-1862. 1999
    1999 Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.AIDS Research and Human Retroviruses.  15:1413-1417. 1999
    1999 A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitisEnfermedades Infecciosas y Microbiologia.  19:213-214. 1999
    1999 Predictors of optimal virological response to potent antiretroviral therapy.AIDS.  13:1873-1880. 1999
    1999 Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team.AIDS.  13:1677-1685. 1999
    1999 Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy.Journal of Infectious Diseases.  180:847-849. 1999
    1999 Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.AIDS Research and Human Retroviruses.  15:1063-1071. 1999
    1999 HIV-1 and HAART: a time to cure, a time to kill.Nature Medicine.  5:609-611. 1999
    1999 Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.Journal of Experimental Medicine.  189:1545-1554. 1999
    1999 Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.Journal of Clinical Investigation.  103:1391-1398. 1999
    1999 A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.Clinical Infectious Diseases.  28:291-296. 1999
    1999 A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.Clinical Infectious Diseases.  28:291-296. 1999
    1999 A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.PharmacoEconomics.  15 Suppl 1:23-37. 1999
    1999 Antiretrovirals for HIV nephropathy?Aids Clinical Care.  11:50. 1999
    1998 Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.AIDS.  12:F203-F209. 1998
    1998 Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.AIDS.  12:F203-F209. 1998
    1998 Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.Nature Medicine.  4:1302-1307. 1998
    1998 Calmodulin antagonists inhibit apoptosis of CD4+ T-cells from patients with AIDS.Immunopharmacology -New York-.  40:91-103. 1998
    1998 Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data.Journal of Infectious Diseases.  178:349-359. 1998
    1998 Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.Journal of the American Medical Association.  280:78-86. 1998
    1998 Controversies in AIDS treatment. Proceedings from CME conference sponsored by Cornell University Medical College and the American Foundation for AIDS Research (AmFAR). November 8, 1997. Faculty roundtable discussion.AIDS patient care.  12:543-555. 1998
    1998 Report of the NIH Panel To Define Principles of Therapy of HIV Infection.Annals of Internal Medicine.  128:1057-1078. 1998
    1998 The changing face of AIDS research and human retroviruses: A new forum to display your ART-workAIDS Research and Human Retroviruses.  14:721. 1998
    1998 Antiretroviral chemotherapy.Current Clinical Topics in Infectious Diseases.  18:154-179. 1998
    1998 Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.Journal of Infectious Diseases.  177:40-47. 1998
    1997 Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT® (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC)Clinical Infectious Diseases.  25:396. 1997
    1997 Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  16:247-253. 1997
    1997 Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.AIDS Research and Human Retroviruses.  13:1533-1537. 1997
    1997 Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group.American Journal of Medicine.  103:223-232. 1997
    1997 Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.New England Journal of Medicine.  337:15-21. 1997
    1997 Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.Journal of the American Medical Association.  277:1962-1969. 1997
    1997 Use of HIV viral load in clinical practice: back to the future.Annals of Internal Medicine.  126:983-985. 1997
    1997 Decreased fat and nitrogen losses in patients with AIDS receiving medium-chain-triglyceride-enriched formula vs those receiving long-chain-triglyceride-containing formula.Journal of The American Dietetic Association.  97:605-611. 1997
    1997 Candidate antiretroviral agents for use in postexposure prophylaxis.American Journal of Medicine.  102:25-31. 1997
    1997 Itraconazole oral solution: pharmacokinetics and absorption.AIDS patient care.  11 Suppl 1:S16-S17. 1997
    1997 Dermatologic manifestations of human immunodeficiency virus infectionCurrent Problems in Dermatology -Chicago then St Louis-.  9:205-242. 1997
    1997 Erratum: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome (New England Journal of Medicine (1997) 337 (15-21))New England Journal of Medicine.  337:1557-1558. 1997
    1997 The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS.Quality of Life Research.  6:3-10. 1997
    1996 Treatment of HIV-1 infection: An overview of new strategies and novel agentsInfections in Medicine.  13:903-911. 1996
    1996 HIV-specific cellular and humoral immune responses in primary HIV infection.AIDS Research and Human Retroviruses.  12:1129-1140. 1996
    1996 Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.Journal of the American Medical Association.  276:146-154. 1996
    1996 HIV viral load markers in clinical practice.Nature Medicine.  2:625-629. 1996
    1996 Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.Annals of Internal Medicine.  124:1019-1030. 1996
    1996 Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection.Proceedings of the National Academy of Sciences.  93:4386-4391. 1996
    1996 Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.Advances in Experimental Medicine and Biology.  394:291-298. 1996
    1996 To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.Aids Clinical Care.  8:1-4. 1996
    1995 A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.New England Journal of Medicine.  333:1534-1539. 1995
    1995 Clinical evaluation of the safety and efficacy of ritonavir (ABT-538), an inhibitor of HIV-1 proteaseMedecine Biologie Environnement.  23:257-265. 1995
    1995 Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology.  10:139-149. 1995
    1995 An approach to antiretroviral treatment of HIV disease. The situation: an overview.Hospital practice (1995).  30 Suppl 1:3-4. 1995
    1995 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group.Clinical Infectious Diseases.  21 Suppl 1:S32-S43. 1995
    1995 Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.Clinical Pharmacology and Therapeutics.  58:44-53. 1995
    1995 Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.AIDS Research and Human Retroviruses.  11:353-361. 1995
    1995 Viral dynamics in human immunodeficiency virus type 1 infection.Nature.  373:117-122. 1995
    1995 Editorialresponse: Clinical and host differences between infections with the two varieties of cryptococcus neoformansClinical Infectious Diseases.  21:35-36. 1995
    1994 Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?Infectious agents and disease.  3:313-323. 1994
    1994 Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.Nature.  370:463-467. 1994
    1994 Evolving understanding of the immunopathogenesis of HIV.AIDS Research and Human Retroviruses.  10:887-892. 1994
    1994 Human immunodeficiency virus infection. American College of Physicians and Infectious Diseases Society of America.Clinical Infectious Diseases.  18:963-973. 1994
    1994 HIV-1 sequence subtype D in the United States.AIDS Research and Human Retroviruses.  10:625-627. 1994
    1994 Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.Clinical Infectious Diseases.  18:789-792. 1994
    1994 What to do when zidovudine fails.New England Journal of Medicine.  330:706-707. 1994
    1994 Issues in combination antiretroviral therapy: a review.Journal of Acquired Immune Deficiency Syndromes.  7 Suppl 2:S24-S35. 1994
    1994 Pathogenicity and diversity of HIV and implications for clinical management: a review.Journal of Acquired Immune Deficiency Syndromes.  7 Suppl 2:S2-10. 1994
    1993 Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.AIDS.  7 Suppl 2:S65-S71. 1993
    1993 Cryptococcal meningitis in AIDS.Hospital Practice.  28:99-112. 1993
    1993 A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.New England Journal of Medicine.  329:1065-1072. 1993
    1993 Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.Proceedings of the National Academy of Sciences.  90:6405-6409. 1993
    1993 A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes.Virology.  194:858-864. 1993
    1993 Viral dynamics in primary HIV-1 infection.Lancet.  341:1099. 1993
    1993 Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.Annals of Internal Medicine.  118:610-616. 1993
    1993 High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.Science.  259:1749-1754. 1993
    1993 In Vitro Effect of Ofloxacin Alone and in Combination with Ceftazidime or Gentamicin against P. aeruginosaDrugs.  45:234-235. 1993
    1993 Response [2]Science.  260:1705-1706. 1993
    1993 Viral dynamics in primary HIV-1 infection [21]Lancet.  341:1099. 1993
    1992 Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group.American Journal of Medicine.  93:489-497. 1992
    1992 Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.Hospital Practice.  27 Suppl 2:26-36. 1992
    1992 A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.New England Journal of Medicine.  326:793-798. 1992
    1992 A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.New England Journal of Medicine.  326:793-798. 1992
    1992 Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.New England Journal of Medicine.  326:83-89. 1992
    1992 Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.New England Journal of Medicine.  326:83-89. 1992
    1991 Primary HIV-1 infection.New England Journal of Medicine.  325:733-735. 1991
    1991 High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.Journal of Infectious Diseases.  164:72-80. 1991
    1991 High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.New England Journal of Medicine.  324:954-960. 1991
    1991 Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer.American Journal of Medicine.  90:418-426. 1991
    1990 The newer antifungal agentsInfections in Medicine.  7:4-8+32. 1990
    1988 Individuals infected with HIV possess antibodies against IL-2.Immunology.  65:611-615. 1988
    1988 Biologically diverse molecular variants within a single HIV-1 isolate.Nature.  334:444-447. 1988
    1988 Extensive variation of human immunodeficiency virus type-1 in vivo.Nature.  334:440-444. 1988
    1988 Treatment of histoplasmosis and blastomycosis.Chest.  93:848-851. 1988
    1988 Azole antifungal agents: emphasis on new triazoles.Antimicrobial Agents and Chemotherapy.  32:1-8. 1988
    1987 The infectious etiology of chronic rheumatic diseases.Seminars in Arthritis and Rheumatism.  17:1-23. 1987
    1987 Brief report: In vitro activity of ciprofloxacin against Neisseria gonorrhoeaeAmerican Journal of Medicine.  82:40-41. 1987
    1986 Q fever endocarditis.American Journal of the Medical Sciences.  292:104-106. 1986
    1986 Q fever endocarditis.American Journal of the Medical Sciences.  292:104-106. 1986
    1986 In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.Antimicrobial Agents and Chemotherapy.  30:25-30. 1986
    1986 Asymptomatic blood donor with a false positive HTLV-III Western blot.New England Journal of Medicine.  314:118. 1986
    1985 Approach to the use of antimicrobial combinations.The Alabama journal of medical sciences.  22:72-75. 1985
    1981 Surgical determination of the site of crossing of jaw-opening reflex evoked by tooth pulp stimulation in the cat.Brain Research.  212:140-144. 1981
    1980 Clinical approach to the choice of antimicrobial therapy, case no. 22: recurrent furunculosis.Journal- Kentucky Medical Association.  78:722-725. 1980
    A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.Topics in antiviral medicine.  24:142-151.
    Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis.Journal of Acquired Immune Deficiency Syndromes.  72:437-443.

    Research Overview

  • HIV / AIDS
    Hepatitis B and C virus infections
  • Principal Investigator On

  • Private Grant  awarded by Gilead Sciences 2018 - 2022
  • Private Grant  awarded by PROTEUS DIGITAL HEALTH, INC. 2017 - 2022
  • Unsolicited R24 CFAR Network of Clinical Systems (CNICS)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2020
  • Private Grant  awarded by Gilead Sciences 2016 - 2020
  • Epidemiology of HIV-Related Atrial Fibrillation  awarded by UNIVERSITY OF WASHINGTON 2017 - 2019
  • Cardiovascular, Pulmonary, & Hematological Disease in HIV: Prevention & Treatment  awarded by UNIVERSITY OF WASHINGTON 2014 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Administrative Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - UAB CFAR - Administrative Supplement Establishment of a HIV-1 Transplant Tissue  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - UAB CFAR- Administrative Supplement CFAR HIV in Women Symposium  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - UAB CFAR- Administrative Supplement-Clinical Core Equipment  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • Developing Research at the Interface of HIV and Aging  awarded by WAKE FOREST UNIVERSITY 2013 - 2019
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2019
  • Private Grant  awarded by Gilead Sciences 2016 - 2019
  • Comprehensive Ascertainment of Hospitalization for Cardiovascular Disease Ascertainment  awarded by ALBERT EINSTEIN COLLEGE OF MEDICINE 2017 - 2018
  • Private Grant  awarded by GlaxoSmithKline 2017 - 2018
  • Private Grant  awarded by Gilead Sciences 2015 - 2018
  • HIV, HCV. and The Menopausal Transition- Effects on Stealosis and Fibrosis Progression  awarded by NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION - NEW 2016 - 2018
  • Comparing Durability, Treatment Failure and Emergence of Resistance of Integrase Strand Transfer Inhibitor Treatment Regimens Among Treatment-Naive and Treatment-Experienced Patients With HIV  awarded by RESEARCH TRIANGLE INSTITUTE 2016 - 2018
  • Private Grant  awarded by Gilead Sciences 2014 - 2018
  • IMPAACT P1115  awarded by Johns Hopkins University 2015 - 2017
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2017
  • Private Grant  awarded by ABBVIE INC 2013 - 2017
  • IMPAACT 1077BF, PROMISE  awarded by Johns Hopkins University 2015 - 2017
  • Private Grant  awarded by MERCK & COMPANY, INC. 2014 - 2017
  • Private Grant  awarded by Gilead Sciences 2015 - 2017
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2017
  • Molecular Methods to Improve Cervical Cancer Screening in HIV+ Women  awarded by ALBERT EINSTEIN COLLEGE OF MEDICINE 2014 - 2017
  • Expanding Our PRO Assessment Integrated into Routine Clinical Care of Patients with HIV to New PROMIS Domains: Identifying Patient Priorities, Developing Cross-Walks with Legacy Instruments, and Evaluating Predictive Validity  awarded by UNIVERSITY OF WASHINGTON 2014 - 2017
  • Private Grant  awarded by Gilead Sciences 2013 - 2017
  • Private Grant  awarded by Gilead Sciences 2013 - 2017
  • UAB-MISS WIHS Cohort  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2016
  • Integration of Evidence-Based Alcohol Interventions into HIV Care  awarded by National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS 2011 - 2016
  • Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by CEPHEID 2015 - 2016
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2016
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Pathways From Food Insecurity to Health and Treatment Outcomes in Women with HIV  awarded by University of California, San Francisco 2014 - 2016
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2013 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2015
  • Private Grant  awarded by MERCK & COMPANY, INC. 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2013 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2015
  • Patient Reported Outcomes in Routine Clinical Care of Patients Infected with HIV  awarded by University of Washington, Seattle 2009 - 2015
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2014 - 2015
  • Private Grant  awarded by Gilead Sciences 2010 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2015
  • Private Grant  awarded by ABBVIE INC 2013 - 2014
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD 2011 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2011 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • The Development of the Creative and Novel Ideas in HIV Research Awards Program  awarded by NIH - OFFICE OF AIDS RESEARCH 2009 - 2014
  • UAB Center for AIDS Research - Administration Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • UAB Center for AIDS Research - Malignancy  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • UAB Center for AIDS Research - Matthews  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • UAB Center for AIDS Research - International Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2011 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2010 - 2014
  • Private Grant  awarded by Gilead Sciences 2010 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Alabama - Clinical Trials Unit  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2013
  • Private Grant  awarded by BOEHRINGER INGELHEIM LTD 2008 - 2013
  • Private Grant  awarded by Gilead Sciences 2011 - 2013
  • Private Grant  awarded by Gilead Sciences 2013
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Private Grant  awarded by Gilead Sciences 2012 - 2013
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2011 - 2013
  • Private Grant  awarded by TOBIRA THERAPEUTICS 2011 - 2013
  • Private Grant  awarded by Gilead Sciences 2011 - 2013
  • Private Grant  awarded by AVEXA LTD 2008 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2008 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2004 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2008 - 2012
  • Private Grant  awarded by TIBOTEC 2008 - 2012
  • Private Grant  awarded by MERCK & COMPANY, INC. 2006 - 2012
  • Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2006 - 2012
  • North Amererican AIDS Cohort Collaboration on Research Design  awarded by Johns Hopkins University 2006 - 2012
  • Private Grant  awarded by JANSSEN R&D IRELAND 2008 - 2012
  • Private Grant  awarded by PROGENICS PHARMACEUTICALS, INC. 2008 - 2012
  • Private Grant  awarded by PROGENICS PHARMACEUTICALS, INC. 2008 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2004 - 2011
  • Recent Advances in AIDS and HIV Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2008 - 2011
  • Private Grant  awarded by TIBOTEC 2011
  • Private Grant  awarded by THERATECHNOLOGIES, INC. 2007 - 2011
  • Private Grant  awarded by MERCK & COMPANY, INC. 2007 - 2011
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2008 - 2011
  • Private Grant  awarded by Pfizer Pharmaceuticals 2007 - 2011
  • Private Grant  awarded by THERATECHNOLOGIES, INC. 2007 - 2011
  • Private Grant  awarded by ARGOS THERAPEUTICS, INC. 2010 - 2011
  • Private Grant  awarded by TIBOTEC 2007 - 2011
  • Private Grant  awarded by AVEXA LTD 2008 - 2009
  • Investigator On

  • Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living with HIV  awarded by University of Pittsburgh 2018 - 2023
  • Viral Adaptation to CD4 T Cell Responses and the Impact on HIV Immunity  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2014 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2022
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • Private Grant  awarded by VIIV HEALTHCARE COMPANY 2016 - 2021
  • 3/3 Alcohol Research Consortium in HIV - Intervention Research Arm (ARCH-IRA)  awarded by National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS 2016 - 2021
  • North American AIDS Cohorts on Collaboration and Design (NAACCORD)  awarded by Johns Hopkins University 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • Alabama Clinical Trials Unit (CTU)  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2017 - 2020
  • Alabama Coalition for Testing, Interventions and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2017 - 2019
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS 2014 - 2019
  • Genetic, Environmental & Histologic Basis for Kidney Disease Risk among Persons Living with HIV  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2019
  • Impact of Antiretroviral Therapy on Liver Fibrosis in Zambian HIV/HBV Patients  awarded by Fogarty International Center/NIH/DHHS 2015 - 2019
  • Prospective Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients  awarded by Johns Hopkins University 2018 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Care Cascade and Discharge Outcomes of Hospitalized HIV + Aambians  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - Developmental Core B  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for AIDS Research - The Role of HIV-Infection and Antiretroviral Therapy Related Mitochondrial Toxicity in Accelerated Aging  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by JANSSEN R&D IRELAND 2016 - 2019
  • AIDS Clinical Trials Group: Protocol Funds FTE Funding  awarded by Brigham and Women's Hospital 2014 - 2018
  • AIDS Clinical Trials Group: Protocol Funds  awarded by Brigham and Women's Hospital 2014 - 2018
  • Private Grant  awarded by MERCK & COMPANY, INC. 2015 - 2018
  • Integrating ENGagement and Adherence Goals upon Entry iENGAGE to Control HIV  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2012 - 2018
  • Development of a Behavioral Intervention for Chronic Pain in Individuals with HIV  awarded by National Institute of Mental Health/NIH/DHHS 2014 - 2017
  • Alabama Coalition for Testing, Interventions, and Engagement in Hepatitis C Care (ACTIVE-Care)  awarded by GILEAD FOUNDATION 2015 - 2017
  • Private Grant  awarded by Gilead Sciences 2012 - 2017
  • Private Grant  awarded by Gilead Sciences 2012 - 2017
  • Inhibition of Herpes Simplex Viruses Type 2 by Tenofovir  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2012 - 2017
  • Effect of Low Dose Methotrexate on Endothelial Function and Inflammation in HIV - A5314  awarded by Brigham and Women's Hospital 2013 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant - Prevalence and Genotype Distribution of Cervical and Oral HPV Infection in HIV+Brazilian Women  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Gilead Sciences 2012 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2012 - 2014
  • UAB Center for AIDS Research - International Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Private Grant  awarded by Gilead Sciences 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by Genentech 2012 - 2014
  • Private Grant  awarded by MERCK & COMPANY, INC. 2008 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013
  • Private Grant  awarded by ABBVIE INC 2013
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2011 - 2013
  • Viremia Copy-Years: Measuring the Effect of Cumulative HIV Burden on Outcomes  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2010 - 2013
  • Adult Clinical Trials Group Protocol #A5272 Supplemental Funds  awarded by SOCIAL & SCIENTIFIC SYSTEMS 2011 - 2012
  • Private Grant  awarded by Gilead Sciences 2012
  • Teaching Overview

  • I attend on the General Medicine (Housestaff) Inpatient Service, Inpatient Infectious Diseases Consult Service, and in the 1917 (HIV) Outpatient Clinic, where I teach Medical Students, Internal Medicine Residents, and Infectious Diseases Fellows. I teach several classes in the Graduate School and Medical School each year, including "Patient, Doctor, and Society" and "Fundamentals II" in the Medical School. I have mentored over 25 trainees who have gone on to successful careers in Academic Medicine and serve as an 'informal mentor' to dozens of young and mid-level faculty members.
  • Education And Training

  • Doctor of Medicine, University of Louisville
  • UAB Hosptial, Chief Resident 1985
  • UAB Hospital, Internship 1982
  • UAB Hospital, Residency 1984
  • UAB Hospital, Postdoctoral Fellowship 1987
  • Full Name

  • Michael Saag
  • Blazerid

  • msaag